Cargando…
MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer
INTRODUCTION: Increasing evidence indicates that microRNAs (miRNAs) are important players in oncogenesis. Considering the widespread use of aromatase inhibitors (AIs) in endocrine therapy as a first-line treatment for postmenopausal estrogen receptor α–positive breast cancer patients, identifying de...
Autores principales: | Vilquin, Paul, Donini, Caterina F, Villedieu, Marie, Grisard, Evelyne, Corbo, Laura, Bachelot, Thomas, Vendrell, Julie A, Cohen, Pascale A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342894/ https://www.ncbi.nlm.nih.gov/pubmed/25633049 http://dx.doi.org/10.1186/s13058-015-0515-1 |
Ejemplares similares
-
ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells
por: Thollet, Aurélie, et al.
Publicado: (2010) -
Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer
por: Vendrell, Julie A., et al.
Publicado: (2019) -
Correlation of microrna-372 upregulation with poor prognosis in human glioma
por: Li, Gang, et al.
Publicado: (2013) -
Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma
por: Li, Bin-Kui, et al.
Publicado: (2014) -
Upregulation of miR-125b is associated with poor prognosis and trastuzumab resistance in HER2-positive gastric cancer
por: Sui, Minghua, et al.
Publicado: (2017)